Home › Compare › CYBNY vs ABBV
CYBNY yields 2857.14% · ABBV yields 3.06%● Live data
📍 CYBNY pulled ahead of the other in Year 1
Combined, CYBNY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CYBNY + ABBV for your $10,000?
Cyber Security 1 AB (publ), a cyber security company, provides cyber services and software solutions in Africa, the Middle East, Europe, and the United Arab Emirates. It operates through three segments: Distribution; Advisory Services; and MSSP/ Managed Services. The company also offers security, risk, and compliance solutions for payment, communication, network, and e-commerce security. In addition, it provides system security, GRC solutions, incident response, and forensics initial license and periodic maintenance agreements covering product updates and customer support; and professional advisory services, which includes legal compliance, installation, and integration of various cyber security system components. Further, the company offers MSSP/Managed services, such as data, network, and gateway securities; and managed compliance and SIEM services, incident response, and business continuity and cyber forensics. It serves public and private sector organizations, including financial, government, healthcare, retail, insurance, manufacturing, and hospitality. The company was formerly known as Cognosec AB (publ) and changed its name to Cyber Security 1 AB (publ) in July 2018. Cyber Security 1 AB (publ) was incorporated in 1970 and is headquartered in Stockholm, Sweden.
Full CYBNY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.